Chronic Pain Clinical Trial
Official title:
Beneficial Effects of Self-hypnosis/Self-care Learning Program for Chronic Pain Patients : a MRI and EEG Study
Chronic pain concerns one in four adults in Belgium. Fibromyalgia is an example of chronic
pain and is characterized by diffused and migrant musculo-tendinous pain localized in the
limbs and at an axial level. The technological improvement in neuroimaging allowed to
improve, at a cerebral level, the identification of the structural and the functional
characteristics of this clinical entity. Studies indicated a modification in cerebral
morphometry showing an alteration of white and grey matter in the anterior cingulate cortex,
orbitofrontal lateral cortex, cerebellum, basal ganglia, insula, secondary somatosensory
cortex, thalamus, amygdala, putamen, superior temporal gyrus and periaqueductal grey matter.
At a functional level, studies show un alteration in the connectivity of the default mode
network, an atrophy of zones implicated in nociception and an increased activation of zone
implicated in response to a nociceptive stimulus.
Nowadays, researchers are interested in finding out the beneficial effects of
non-pharmacological techniques to improve de well-being of patients with chronic pain.
Hypnosis is one of these techniques that has already proven to be successful in decreasing
pain and improving global quality of life. Nevertheless, to our knowledge, no study has been
conducted to understand the impact of hypnosis upon the cerebral functioning of these
patients. Therefore, the aim of this study is to understand the impact of a 6 months
self-hypnosis/self-care learning program upon the structural and functional functioning of
the brain by means of functional magnetic resonance imagery (fMRI) and electroencephalography
(EEG).
Status | Recruiting |
Enrollment | 60 |
Est. completion date | March 30, 2020 |
Est. primary completion date | January 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Major - Fluency in French - Fibromyalgia diagnosis Exclusion Criteria: - Neurologic disorder - Psychiatric disorder - Drug addiction - Alcoholism |
Country | Name | City | State |
---|---|---|---|
Belgium | Hospital University of Liège | Liège |
Lead Sponsor | Collaborator |
---|---|
University of Liege | Fondation Benoit |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in pain description | The impact of self-hypnosis/self-care on pain description will be assessed by means of a Visual Analogue Scale (VAS). Scale ranging from 0 (no pain) to 10 (worst pain). | Day 0 (first meeting with the doctor), up to 5 months (before the intervention), up to 12 months (after the intervention) | |
Primary | Change in sleep difficulties | The impact of self-hypnosis/self-care upon the severity of insomnia will be assessed by means of the "Insomnia Severity Index" (Morin et al., 2001). Scale ranging from 0 (none) to 4 (very severe). | Day 0 (first meeting with the doctor), up to 5 months (before the intervention), up to 12 months (after the intervention) | |
Primary | Change in anxiety | The impact of self-hypnosis/self-care on anxiety will be assessed by means of the subtest "anxiety" of the Hospital Anxiety and Depression Scale (HADS, Zigmond & Snaith, 1983). Scale ranging from 0 (never) to 4 (always). | Day 0 (first meeting with the doctor), up to 5 months (before the intervention), up to 12 months (after the intervention) | |
Primary | Change in depression | The impact of self-hypnosis/self-care on depression will be assessed by means of the subtest "anxiety" of the Hospital Anxiety and Depression Scale (HADS, Zigmond & Snaith, 1983). Scale ranging from 0 (never) to 4 (always). | Day 0 (first meeting with the doctor), up to 5 months (before the intervention), up to 12 months (after the intervention) | |
Primary | Change in pain disability | The impact of self-hypnosis/self-care on pain disability will be assessed by means of the "Pain Disability Index" (PDI, Tait et al., 1990). Scale ranging from 0 (no difficulties) to 10 (a lot of difficulties). | Day 0 (first meeting with the doctor), up to 5 months (before the intervention), up to 12 months (after the intervention) | |
Primary | Change in attitudes and beliefs about pain | The impact of self-hypnosis/self-care on the attitudes and beliefs about pain will be assessed my means of the "Survey of Pain Attitudes" (SOPA, Jensen & Karoly, 1987). Scale ranging from 0 (totally wrong) to 10 (totally right). | Day 0 (first meeting with the doctor), up to 5 months (before the intervention), up to 12 months (after the intervention) | |
Primary | Change in quality of life | The impact of self-hypnosis/self-care on the quality of life will be assessed by means of the "Short Form-36"(SF-36; Ware et al., 1988). Each item is balanced to obtain a score between 0 (worst quality) to 100 (maximum quality). | Day 0 (first meeting with the doctor), up to 5 months (before the intervention), up to 12 months (after the intervention) | |
Primary | Change in locus of control | The impact of self-hypnosis/self-care on the locus of control will be assessed my means og the "Multidimensional Health Locus of Control" (MHLC, Wallston et al., 1978). Scale ranging from 1 (no agreement) to 4 (agreement). | Day 0 (first meeting with the doctor), up to 5 months (before the intervention), up to 12 months (after the intervention) | |
Primary | Change of the impact of pain | The impact of self-hypnosis/self-care on the impact of pain in individual's life, quality of social support and general activity, will be assessed my means of the "Multidimensional Pain Index" (PDI, Kerns et al., 1985). Scale ranging from 0 (none) to 6 (a lot). | Day 0 (first meeting with the doctor), up to 5 months (before the intervention), up to 12 months (after the intervention) | |
Primary | Change in generic health | The impact of self-hypnosis/self-care on generic health will be assessed by the "EuroQol 5 Dimensions" questionnaire (EQ-5D, Health Policy, 1990). Scale ranging from 1 (no problems) to 3 (extreme problems). | Day 0 (first meeting with the doctor), up to 5 months (before the intervention), up to 12 months (after the intervention) | |
Primary | Change in health status | The impact of Self-hypnosis/self-care on global health status will be assessed by means of a Visual Analogue Scale (VAS). Scale ranging from 0 (worst health status) to 100 (best health status). | Day 0 (first meeting with the doctor), up to 5 months (before the intervention), up to 12 months (after the intervention) | |
Primary | Change in physical activity | The impact of self-hypnosis/self-care on the physical activity will be assessed by means of the International Physical Activity Questionnaire (Craig et al., 2003). Participants have to describe the amount of low to intense physical activity they did over a period of 7 days. | Day 0 (first meeting with the doctor), up to 5 months (before the intervention), up to 12 months (after the intervention) | |
Primary | Motivation to change | The impact of self-hypnosis/self-care on the motivation to change will be assessed by means of the "University of Rhode Island Change Assessment" (URICA, DiClemente et al., 1990). Scale ranging from 1 (no agreement) to 5 (agreement). | Day 0 (first meeting with the doctor), up to 5 months (before the intervention), up to 12 months (after the intervention) | |
Primary | Impact on return-to-work | For participants who continued to work at time of inclusion, the "Work Design Questionnaire" (WDQ, Morgeson & Hymphrey, 2006) will be administered. Scale ranging from 0 (not at all) to 5 (exactly). | Day 0 (first meeting with the doctor), up to 5 months (before the intervention), up to 12 months (after the intervention) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|